Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
A phase 3 trial of Flutamide and Triptorelin in Prostate cancer, run by UNICANCER, completed.
Overview
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer is a phase 3 interventional study registered as NCT00104741 by UNICANCER, with 378 participants recorded, started 2003-09-10 and reaching its primary completion in 2015-10. Interventions recorded: flutamide, triptorelin, radiation therapy. Conditions recorded: Prostate Cancer.
Linked to the drug Flutamide because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialProstate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Shares Flutamide, Triptorelin, Prostate cancer and the tag pipeline.
- TrialEffect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
Shares Triptorelin, Prostate cancer and the tag pipeline.
- TrialRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Shares Flutamide, Triptorelin, Prostate cancer and the tag pipeline.
- TrialFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Shares Flutamide, Prostate cancer and the tag pipeline.
- TrialHormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Shares Flutamide, Prostate cancer and the tag pipeline.
- TrialTriptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Shares Triptorelin and the tag pipeline.
- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Flutamide, Triptorelin, Prostate cancer and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Flutamide, Triptorelin, Prostate cancer and the tag pipeline.